The probe or sensor, known as spinalNET, is used to explore how neurons in the spinal cord process sensation and control movement. Photo by Jeff Fitlow/Rice University

A team of Rice University engineers has developed an implantable probe over a hundred times smaller than the width of a hair that aims to help develop better treatments for spinal cord disease and injury.

Detailed in a recent study published in Cell Reports, the probe or sensor, known as spinalNET, is used to explore how neurons in the spinal cord process sensation and control movement, according to a statement from Rice. The research was supported by the National Institutes of Health, Rice, the California-based Salk Institute for Biological Studies, and the philanthropic Mary K. Chapman Foundation based in Oklahoma.

The soft and flexible sensor was used to record neuronal activity in freely moving mice with high resolution for multiple days. Historically, tracking this level of activity has been difficult for researchers because the spinal cord and its neurons move so much during normal activity, according to the team.

“We developed a tiny sensor, spinalNET, that records the electrical activity of spinal neurons as the subject performs normal activity without any restraint,” Yu Wu, a research scientist at Rice and lead author of the study said in a statement. “Being able to extract such knowledge is a first but important step to develop cures for millions of people suffering from spinal cord diseases.”

The team says that before now the spinal cord has been considered a "black box." But the device has already helped the team uncover new findings about the body's rhythmic motor patterns, which drive walking, breathing and chewing.

Lan Luan (from left), Yu Wu, and Chong Xie are working on the breakthrough device. Photo by Jeff Fitlow/Rice University

"Some (spinal neurons) are strongly correlated with leg movement, but surprisingly, a lot of neurons have no obvious correlation with movement,” Wu said in the statement. “This indicates that the spinal circuit controlling rhythmic movement is more complicated than we thought.”

The team said they hope to explore these findings further and aim to use the technology for additional medical purposes.

“In addition to scientific insight, we believe that as the technology evolves, it has great potential as a medical device for people with spinal cord neurological disorders and injury,” Lan Luan, an associate professor of electrical and computer engineering at Rice and a corresponding author on the study, added in the statement.

Rice researchers have developed several implantable, minimally invasive devices to address health and mental health issues.

In the spring, the university announced that the United States Department of Defense had awarded a four-year, $7.8 million grant to the Texas Heart Institute and a Rice team led by co-investigator Yaxin Wang to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation.

That same month, the university shared news that Professor Jacob Robinson had published findings on minimally invasive bioelectronics for treating psychiatric conditions. The 9-millimeter device can deliver precise and programmable stimulation to the brain to help treat depression, obsessive-compulsive disorder and post-traumatic stress disorder.
The Texas Medical Center has named its second cohort for its United Kingdom-focused health tech accelerator. Photo via TMC

16 digital health, medical device companies selected for UK, TMC accelerator

coming to Hou

For the second time, an accelerator backed by the United Kingdom and hosted by Texas Medical Center Innovation has named 16 companies to its new cohort.

In partnership with Innovate UK, TMC named the new cohort companies in an announcement this week. The companies are divided into two categories — digital health and medical device — and cover a wide range of specialties, from diagnostics and AI monitoring to non-surgical management and more.

The accelerator launched last year with its inaugural cohort with the mission of helping companies make their United States expansion by way of the TMC.

"The first cohort of startups in our accelerator program experienced TMC's capabilities in developing and advancing solutions through cross-collaboration with top minds in clinical care, commercialization and innovation," Devin Dunn, head of the Accelerator for Health Tech at TMC, says in a news release. "We are excited to continue our partnership with Innovate UK and welcome this second cohort to continue our efforts advancing life sciences technologies across the globe."

This year's program begins June 4 and will run through November. According to the TMC, last year's cohort had significant success tapping into the health tech ecosystem in Houston, including engaging with investors, setting up a go-to-market strategy, and making inaugural U.S.-based hires.

“Our Global Incubator Programme selects driven and ambitious innovators looking to scale their technologies globally," adds Jon Hazell, partnership manager for the North America and Global Incubator at Innovate UK. "We are excited for our second cohort of startups to join the programme, supported by the Texas Medical Center accelerator, where world-class mentors and programming will help our entrepreneurs understand and meet the requirements of different markets, and build the necessary partnerships, collaborations, and networks, facilitating their entry into global markets."

The selected medical device companies — and their technologies, as described by the TMC — include:

  • Cytecom – infectious diagnostic test, powered by cutting-edge optical electrophysiology, detects resistant bacteria in just 45 seconds, enabling doctors to prescribe targeted antibiotics in minutes instead of days
  • Heartfelt Technologies Ltd – the future of heart failure telemonitoring an automatic, AI supported, non-contact telemonitoring solution for heart failure patients
  • Neurovalens Ltd – creates wearable neurostimulaton devices that treat a range of conditions in an entirely non-invasive and drug-free way
  • Oxford Medical Products Limited – a proprietary hydrogel pill that acts as a non-surgical, non-pharmacological obesity treatment that will redefine the obesity treatment market
  • Phenutest – a rapid point-of-care diagnostic test for urinary tract infection, that confirms infection and appropriate antimicrobial to prescribe within 60 minutes
  • Plexaa – world's first fully wearable, sensor controlled, bra insert that can deliver safe supraphysiological preconditioning to the breast skin the night before surgery at home
  • SolasCure Limited – a wound Gel that acts as a single, effective and easy-to-use solution to overcome the challenges to transform chronic wound care
  • Trueinvivo Limited – a proprietary dosimetry (radiation measurement) system to ensure the precision and accuracy of cancer radiotherapy

The selected digital health companies — and their technologies, as described by the TMC — include:

  • Axon Diagnostics – offers a suite of solutions to support the needs of modern day diagnostic imaging services, supporting happier lives for clinicians and helping deliver better diagnostic care for all
  • Kheiron Medical Technologies – regarded as a world leader in the development of AI-enabled cancer diagnostics and monitoring
  • KiActiv – a technology-enabled digital health model for behaviour change and self-care that rethinks exercise and makes everyday movement an effective personalized medicine for better clinical outcomes
  • Memory Lane Games – turns memories into games, offering care providers a simple, fun dementia engagement app designed to trigger positive memories and improve socialisation with caregivers and people living with dementia
  • NeuroVirt Limited – combines immersive VR, AI and computer vision to gamify rehabilitation and quantify patient impairment and improvement
  • Newton’s Tree – enables healthcare providers to procure, integrate, and monitor third party AI products as part of routine care pathways through its enterprise AI platform
  • SERG Technologies – uses patented sensor technology and artificial intelligence to transform disease management into a continuous, data driven, and patient specific approach for people with Parkinson’s
  • Thymia – leverages speech, video, and behavioral analytics gathered via specially designed video games to diagnose conditions like depression, anxiety, and ADHD, alongside critical symptoms like fatigue, mood fluctuations, and memory issues, creating novel mental health biomarkers
The partnership between the U.K. and TMC began in 2018 as a biobridge between the two entities. TMC has expanded into new biobridges with other countries — most recently with The Netherlands — and also has a Danish accelerator that's also running its second cohort this summer.
VenoStent's innovative medical device is officially enrolling subjects in a clinical trial. Image courtesy of VenoStent

Houston startup with unique vascular innovation enrolls subjects in new trial

medical device momentum

A Houston-based company has enrolled the initial subjects in a first-of-its-kind trial.

VenoStent was created to improve vascular surgery outcomes for patients undergoing arteriovenous fistula (AVF) creation surgery.

“When a vein is connected to an artery, as in AVF creation, the vein experiences a 10x increase in pressure and flow that is traumatizing to veins. Many fail to become usable for dialysis,” Geoffrey Lucks, VenoStent COO and co-founder, says in a news release.

Enter VenoStent’s SelfWrap Bioabsorbable Perivascular Wrap, better known as simply SelfWrap. In May 2023, SelfWrap gained FDA approval to begin its US IDE Study, SAVE-FistulaS: The SelfWrap-Assisted ArterioVEnous Fistula Study.

Roughly half a million Americans need hemodialysis just to survive another day. Nearly all of those patients require a vascular access creation surgery, but the procedure has a 50-percent failure rate in its first year. VenoStent and SelfWrap are aimed at improving those odds. It works by using the body’s own healing mechanism.

SelfWrap is a flexible, bioabsorbable vascular wrap that helps to recreate the arterial environment in veins. Over time, the body replaces the SelfWrap with venous tissue.

The company has begun to enroll patients for what will eventually be a 200-subject study. Some of those people have radiocephalic fistulas, others have brachiocephalic ones. This is important, because it will likely prove that the technology works for most types of AVFs. The sites for this clinical trial are at the Surgical Specialists of Charlotte, P.A. in Charlotte, NC, and the Cardiothoracic and Vascular Surgeons in Austin.

“While it’s ambitious and sets a high bar for FDA Approval, we owe it to the chronic kidney disease (CKD) patient community to provide the highest level of clinical evidence,” Timothy Boire, CEO and cofounder, says in the release. “We’re confident based on years of preclinical and clinical data that we’ll demonstrate superiority to standard of care with this breakthrough technology.”

VenoStent recently completed a $16 million Series A, financed by Good Growth Capital and IAG Capital. This is the first-ever randomized controlled trial of a medical device designed to improve outcomes from arteriovenous fistula (AVF) creation surgery in the United States.

Motif Neurotech, which develops minimally invasive bioelectronics for mental health treatment, closed its series A round with an oversubscribed $18.75 million. Photo via Rice.edu

Rice University medical device spinout secures nearly $19M series A

fresh funding

A health tech startup based out of a newly formed accelerator program at Rice University has raised venture funding.

Motif Neurotech closed its series A round with an oversubscribed $18.75 million. The company, which develops minimally invasive bioelectronics for mental health treatment, was formed out of the Rice Biotech Launch Pad that launched last fall.

The round was led by Arboretum Ventures, with participation from new investors KdT Ventures, Satori Neuro, Dolby Family Ventures, re.Mind Capital and existing investors Divergent Capital, TMC Venture Fund, PsyMed Ventures, Empath Ventures and Capital Factory, according to a news release from Rice.

“Minimally invasive bioelectronics are the future of mental health treatment,” Jacob Robinson, CEO and founder of Motif Neurotech, says in the release. “Thirty percent of patients with depression don’t respond to two or more medications, and there is a significant need for additional treatment options that are effective and easily accessible."

The fresh funding will go toward developing the inaugural product, the DOT microstimulator, a wireless, battery-free device that can provide at-home therapy for treatment-resistant depression, or TRD, a major depressive disorder.

“This is a pivotal moment for the company as it closes its Series A in addition to the recent successful completion of the proof-of-concept first-in-human implant of the DOT stimulator device," Tom Shehab, managing partner of Arboretum Ventures, says in the release. "We believe Motif’s device will greatly improve the quality of life for patients who have been diagnosed with difficult to treat mental health disorders, including TRD."

Shehab, along with Amy Kruse, chief investment officer of Satori Neuro, will reportedly join Motif Neurotech's board of directors alongside Anthony Arnold, president and CEO of Sensydia Corporation, and Jacob Robinson, professor of electrical and computer engineering and bioengineering at Rice.

The Rice Biotech Launch Pad was established to take biotech innovations from concept to clinical trials in five years or less. It occupies 15,000 square feet of space on campus and is funded through federal grants and donations.

A unique innovation from the University of Houston has the potential to help stroke victims recover mobility. Photo courtesy of UH

Houston innovator makes major headway on his portable stroke rehab device

research milestone

A University of Houston professor has taking a huge step in advancing his game-changing stroke recovery tech.

Jose Luis Contreras-Vidal, the director of the UH BRAIN Center, recently published his work on a noninvasive brain-machine in a summer issue of the journal Sensors. InnovationMap first reported on Contreras-Vidal's technology in 2022, when it was being tested.

Contreras-Vidal's device uses a wireless, mobile dry-electrode headset placed on the scalp to convert electroencephalography (EEG) recordings (or measurements of electrical activity in different parts of the brain) to interface with a closed-loop brain–computer (BCI) and communicate with exoskeleton devices. Together, the technology triggers robotic movement based on the wearer's brain activity.

The technology has potential to boost cortical plasticity after a stroke, which can improve motor skills recovery.

According to a statement from UH, a patent is pending on Contreras-Vidal's BCI algorithm and the self-positioning dry electrode bracket used on the scalp. The technology has also now been validated and tested at the University of Houston.

Contreras-Vidal says the technology makes stroke recovery easier for the user and even possible at home.

“Most commercial EEG-based BCI systems are tethered to immobile processing hardware or require complex programming or set-up, making them difficult to deploy outside of the clinic or laboratory without technical assistance or extensive training," he says in a statement. "A portable and wireless BCI system is highly preferred so it can be used outside lab in clinical and non-clinical mobile applications at home, work, or play.”

Additionally, the technology uses off-the-shelf components and is adjustable to fit about 90 percent of the population, according to UH.

"Current commercial EEG amplifiers and BCI headsets are prohibitively expensive, lack interoperability, or fail to provide a high signal quality or closed-loop operation, which are vital for BCI applications,” Contreras-Vidal adds.

The development of this technology was originally funded in part by an $813,999 grant from the National Science Foundation’s Division of Translational Impacts. UH reports that about 795,000 people in the United States suffer from a stroke annually.

Other leaders in Houston’s medical industry have tapped into innovative ways to treat and rehabilitate stroke patients in recent years. Baylor St. Luke's Hospital began using AI to reduce the time it takes to treat patients who've suffered from a stroke in 2021.

A Houston startup based out of the TMC Innovation Factory has announced funding and upcoming trials. Photo courtesy of TMC

Houston health tech startup secures $16M series A, prepares for first U.S. clinical trials

money moves

Fueled by fresh funding in the bank, a medical device startup has announced upcoming trials.

VenoStent, Inc., a company developing an innovative tool to improve outcomes for hemodialysis patients, has closed $16 million in a series A round of financing. Two Charleston, South Carolina-based firms — Good Growth Capital and IAG Capital Partners — led the round.

The company also announced it received Investigational Device Exemption from the FDA for its United States clinical trial, SAVE-FistulaS.

“Our mission at VenoStent is to improve the quality and length of life of dialysis patients. On the heels of our very promising results in several preclinical studies and a 20-patient feasibility study that led to our Breakthrough Designation last year, this recent IDE approval is perhaps our biggest milestone to date," Tim Boire, CEO of VenoStent, says in a news release. "We now enter an exciting new epoch in our company’s development that we believe will ultimately result in FDA Approval and vastly improve the quality and length of life for patients."

VenoStent's novel therapeutic medical device is a bioabsorbable wrap. Image courtesy of VenoStent

VenoStent's series A will fund the trial, expand manufacturing capabilities, and more. The company is targeting the more than 800,000 people in the U.S. with end-stage renal disease. Currently, more than half of the surgeries performed to initiate hemodialysis fail within a year. VenoStent's novel therapeutic medical device is a bioabsorbable wrap that reduces vein collapse by providing mechanical support and promoting outward vein growth.

“This trial is designed to provide the highest level of clinical evidence. We’re excited to be in this position to treat the first patients in the United States with this technology, and demonstrate the safety and efficacy of our device,” continues Boire in the release.

Per the release, the company is aiming for FDA Approval and be the first-to-market device to improve hemodialysis access surgery.

“We’re extremely pleased to be partnering with VenoStent on this critical mission. This company and technology are poised for commercial success to address a critical, unmet need,” says Bob Crutchfield, operating partner at Good Growth Capital, in the release.

The TMC Venture Fund also contributed to the series A investment round, along with SNR, Baylor Angel Network / Affinity Fund, Creative Ventures, Cowtown Angels, Alumni Ventures, and other notable angel investors. Past investors in VenoStent include KidneyX, National Science Foundation, National Institute of Health, Y Combinator, Health Wildcatters, and the Texas Halo Fund.

“VenoStent’s data and traction to date is impressive and gives us a lot of confidence in their continued success. We look forward to helping them get this Breakthrough product to market and help patients that are in dire need of this innovative technology,” says Joel Whitley, partner at IAG Capital Partners, in the release.

Tim Boire is the CEO of VenoStent. Photo via LinkedIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC med-tech company closes $2.5M series A, plans expansion

fresh funding

Insight Surgery, a United Kingdom-based startup that specializes in surgical technology, has raised $2.5 million in a series A round led by New York City-based life sciences investor Nodenza Venture Partners. The company launched its U.S. business in 2023 with the opening of a cleanroom manufacturing facility at Houston’s Texas Medical Center.

The startup says the investment comes on the heels of the U.S. Food and Drug Administration (FDA) granting clearance to the company’s surgical guides for orthopedic surgery. Insight says the fresh capital will support its U.S. expansion, including one new manufacturing facility at an East Coast hospital and another at a West Coast hospital.

Insight says the investment “will provide surgeons with rapid access to sophisticated tools that improve patient outcomes, reduce risk, and expedite recovery.”

Insight’s proprietary digital platform, EmbedMed, digitizes the surgical planning process and allows the rapid design and manufacturing of patient-specific guides for orthopedic surgery.

“Our mission is to make advanced surgical planning tools accessible and scalable across the U.S. healthcare system,” Insight CEO Henry Pinchbeck said in a news release. “This investment allows us to accelerate our plan to enable every orthopedic surgeon in the U.S. to have easy access to personalized surgical devices within surgically meaningful timelines.”

Ross Morton, managing Partner at Nodenza, says Insight’s “disruptive” technology may enable the company to become “the leader in the personalized surgery market.”

The startup recently entered a strategic partnership with Ricoh USA, a provider of information management and digital services for businesses. It also has forged partnerships with the Hospital for Special Surgery in New York City, University of Chicago Medicine, University of Florida Health and UAB Medicine in Birmingham, Alabama.

2 Houston suburbs named among 10 best places to live by U.S. News & World Report

Where to Live

The Houston suburbs of Pearland and League City have landed among the top 10 best places to live in 2025, according to U.S. News & World Report.

New for the 2025-2026 "Best Places to Live in the U.S." rankings, U.S. News expanded its coverage from 150 to 250 U.S. cities, and updated its methodology to examine each city based on five livability indexes: Quality of life, value, desirability, job market, and net migration.

Pearland ranked No. 3 nationwide, earning a 7.0 score alongside No. 1-winning Johns Creek, Georgia and No. 2 winner Carmel, Indiana.

Pearland also landed on top of U.S. News separate rankings of the best places to live in Texas for 2025-2026.

Some facts about Pearland that put it at the top of the list include its median household income ($115,504), its median home values ($319,753), and its bustling population of nearly 124,000 residents.

Housing costs in Pearland are extremely attractive compared to other places in the country, as the national average home is worth over $370,000. It's no wonder this Houston neighbor has been adding more high-income households than many other places in Texas.

Pearland's population is a healthy mix of young individuals and families, with 29 percent of residents under 20 years old and 36 percent of the population between the ages of 20-44. Nearly a quarter of Pearland's population is between 45-64-years-old, while only 12 percent of residents are over 65, the report says.

Pearland's reputation as one of the safest cities in America is also boosting its community appeal.

Pearland Pear TrailPearland's Pear-Scape Trail is a popular public art trail that residents, families, and visitors can enjoy. The sculptures are scattered all over the city.City of Pearland - Government/Facebook

"Finding a community to be part of can play a major role in making a place feel like home," U.S. News said. "If you’re a parent with young children, you may want to live in a neighborhood with other people in that phase of life. If you’re a professional moving to a hot job market for your field, you may want to live in an apartment close to the office or within walking distance of friends and colleagues."

Pearland also enjoys a better job market than other cities, the report added. Pearland's unemployment rate as of 2023 was only 3.6 percent, lower than the national average unemployment rate of 4.5 percent.

However, if people are looking for a public transportation-friendly city, they may need to look elsewhere. Almost all commuters in Pearland drive to their workplaces, making access to a vehicle absolutely necessary for living in the suburb. Pearland's 31.2-minute average commute time is also 9.2 minutes higher than the national average, U.S. News said.

Other Houston-area suburbs

League City ranked three spots behind Pearland as the 6th best place to live in the U.S., and No. 2 in Texas. The city boasts a median household income of $120,670, and affordable median home values at $327,511.

Workers in League City also predominantly rely on vehicles for their daily commutes, and only 3.7 percent of the population use public transport to get to work. Commuters spend an average time of 27.5 minutes driving to work, U.S. News determined.

More than half (63.5 percent) of all League City residents are married, and 54 percent of the population are between the ages of 25 and 64-years-old.

Here's how other Houston-area cities faired among the top 100:

  • No. 16 – Sugar Land
  • No. 44 – The Woodlands
  • No. 45 – Katy
  • No. 67 – Missouri City
  • No. 73 – Spring

Houston drops out of the top 100

Though Houston proper made substantial improvements to land among the top 100 best places to live in U.S. News' 2024-2025 report, the city has once again plummeted toward the bottom of the list for 2025-2026.

Houston slumped to No. 381 this year, and only ranked No. 63 in the statewide comparison, showing that the city has lost its charm in favor of its appealing suburban neighbors.

The top 10 best places to live in the U.S. are:

  • No. 1 – Johns Creek, Georgia
  • No. 2 – Carmel, Indiana
  • No. 3 – Pearland, Texas
  • No. 4 – Fishers, Indiana
  • No. 5 – Cary, North Carolina
  • No. 6 – League City, Texas
  • No. 7 – Apex, North Carolina
  • No. 8 – Leander, Texas
  • No. 9 – Rochester Hills, Michigan
  • No. 10 – Troy, Michigan
---

This story originally appeared on CultureMap.com.

9 can't-miss Houston business and innovation events for June

where to be

Editor's note: From lightning pitches to a female-focused AI summit and energy conferences, there's still plenty to do as Houston settles into the summer. Here are the Houston business and innovation events you can't miss in June and how to register. Please note: this article might be updated to add more events.


June 3 – Founders Live Houston 

Watch five Houston founders present their 99-second pitches at Founders Live Houston. Competing teams include AyeDu (Vinita Gupta), Omniscale (Tony Hernandez-Ferman), AnswerPath (Chris Mullins), Katana.video (Sam Bhattacharyya) and TraceWrap (Laketta B.).

This event is Tuesday, May 3, at 5:30 p.m. at the Ion. Register here.

June 4 – Center for Human Performance Research & Networking Event

Rice University and Houston Methodist's Center for Human Performance will host an event to support its work in the study of exercise physiology, injury prevention and rehabilitation. The organizations will share more information on seed grant opportunities, and the event will feature presentations from Rice and Houston Methodist leaders, networking sessions and a poster showcase.

This event is Wednesday, June 4, from 3-5:30 p.m. at the BioScience Research Collaborative at Rice University. Register here.

June 12 – Transition on Tap

Meet and hear lighting pitches from eight of Greentown Labs’ newest startup members. Attendees can network with entrepreneurs, investors, corporate leaders, philanthropists, students and other climate champions. Georgina Campbell Flatter, CEO of Greentown Labs, and Victor Martinez, Greentown's memberships manager, will also speak.

This event is Thursday, June 12, from 5:30-7:30 p.m. at Greentown Houston. Register here.

June 16-18 — Energy Drone & Robotics Summit

This three-day summit, the largest of its kind, will connect 1,500-plus leaders in the global energy/industrial robotics, drone and data sectors. Attendees will glean the latest ideas, use cases, best practices, tech and trends from a wide variety of robotics and drone industry experts.

This event begins June 16 at Woodlands Waterway Marriott. Register here.

June 17 – SGSF’s #SUPERGirlsInSTEM Summit, The Intersection of AI & Workforce

SUPERGirls SHINE Foundation is hosting a one-day summit for women ages 18-24 focused on the evolving intersection of AI and the STEM workforce. The conference will feature keynote speakers, panel discussions and hands-on workshops.

This event is Tuesday, June 17, from 9 a.m.-1 p.m. at the Ion. Register here.

June 18 – 2025 Obsidi BNXT: Juneteenth Tech Forum

Obsidi.com, an online platform launched by the Black Professionals in Tech Network (BPTN), will host a forum for high-performing Black and allied tech executives. The event offers networking opportunities, keynotes and panels that feature executives from Echelon Health Partners, Hewlett-Packard Enterprise, SAP, Intuit and more.

The event is Wednesday, June 18, at NRG Center. Register here.

June 24 — Houston Methodist Leadership Speaker Series

Head to the Houston Methodist Tech Hub at Ion to hear the latest installment of the Houston Methodist Leadership Speaker Series. Trent Fulin, vice president and CEO at Houston Methodist Cypress Hospital, will discuss the new 105-acre campus and its first 100 days of patient care, followed by a Q&A.

This event is Tuesday, June 23, from 4:45-6 p.m. Register here.

June 25-26 – Carbon Capture Technology Expo and  Hydrogen Technology Conference & Expo North America

Tackling climate change is one of the biggest global challenges that requires immediate action, and many industrial sectors are now looking to new technology to help meet net-zero emission targets. The Carbon Capture Technology Expo is North America's leading event for carbon capture, utilization and storage. The expo offers opportunities to network with industry frontrunners and best-in-class solution providers.

This event begins June 25 at NRG Center. Click here to register. It is co-located with the Hydrogen Technology Conference & Expo North America. Expo passes are free.

June 26 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing and how Houston’s innovation community can leverage them. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 26, from 6-7 p.m. at the Ion. Register here.